October 01, 2020
4 min watch
Save
Exciting approvals, treatments in the pipeline for anemia management in CKD
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical officer for dialysis at Indiana University Health in Indianapolis discusses exciting new agents in the pipeline, including hypoxia-inducable factor stabilizers (HIF).
Click here to watch the next video in the series on needed improvements in anemia management of CKD.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Wish reports advisory board roles for Akebia, AstraZeneca, Vifor and Rockwell Medical, and speaker’s bureau for Akebia and AstraZeneca.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.